Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Endometrial Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × GSK2141795 × Clear all
NCT01907815 2018-04-06

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
24 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡